by: Parent Project Muscular DystrophyNS Pharma Announcement of VILTEPSO™ (viltolarsen) – A New FDA-Approved Treatment for Patients With Duchenne Amenable to Exon 53 Skipping (August 26, 2020 Webinar)
NS Pharma joined PPMD for a webinar on August 26, 2020 to provide an update about VILTEPSO™ from Ben Yungher, PhD, NS Pharma’s Medical Science Liaison, and its associated patient support program from Randy McGonigal, NS Pharma’s Director of Market Access.
